PL4055055T3 - Bispecific antibodies against ceacam5 and cd47 - Google Patents
Bispecific antibodies against ceacam5 and cd47Info
- Publication number
- PL4055055T3 PL4055055T3 PL21834934.8T PL21834934T PL4055055T3 PL 4055055 T3 PL4055055 T3 PL 4055055T3 PL 21834934 T PL21834934 T PL 21834934T PL 4055055 T3 PL4055055 T3 PL 4055055T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies against
- bispecific antibodies
- against ceacam5
- ceacam5
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pens And Brushes (AREA)
- Conversion Of X-Rays Into Visible Images (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20215766 | 2020-12-18 | ||
US202163135996P | 2021-01-11 | 2021-01-11 | |
PCT/IB2021/061983 WO2022130348A1 (en) | 2020-12-18 | 2021-12-17 | Bispecific antibodies against ceacam5 and cd47 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL4055055T3 true PL4055055T3 (en) | 2024-04-15 |
Family
ID=79164846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL21834934.8T PL4055055T3 (en) | 2020-12-18 | 2021-12-17 | Bispecific antibodies against ceacam5 and cd47 |
Country Status (16)
Country | Link |
---|---|
US (2) | US11753481B2 (en) |
EP (1) | EP4055055B1 (en) |
JP (1) | JP2024501809A (en) |
KR (1) | KR20230121772A (en) |
AU (1) | AU2021400227A1 (en) |
CA (1) | CA3193210A1 (en) |
CL (1) | CL2023001797A1 (en) |
CO (1) | CO2023009100A2 (en) |
ES (1) | ES2967381T3 (en) |
HR (1) | HRP20240213T1 (en) |
IL (1) | IL301701A (en) |
MX (1) | MX2023007220A (en) |
PE (1) | PE20231386A1 (en) |
PL (1) | PL4055055T3 (en) |
RS (1) | RS65211B1 (en) |
WO (1) | WO2022130348A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210029158A (en) * | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Bispecific antibodies to CEACAM5 and CD47 |
ES2967381T3 (en) | 2020-12-18 | 2024-04-30 | Lamkap Bio Beta Ag | Bispecific antibodies against CEACAM5 and CD47 |
US20240002544A1 (en) * | 2022-03-07 | 2024-01-04 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294372B1 (en) | 1997-03-14 | 2001-09-25 | University Of Victoria Innovation & Dev. Corp. | Replication genes and gene products from small cryptic plasmids and methods for constructing controlled-replication plasmid vectors |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
ES2367430T3 (en) | 2002-12-23 | 2011-11-03 | Wyeth Llc | ANTIBODIES AGAINST PD-1 AND ITS USES. |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
AU2003265522A1 (en) | 2003-08-18 | 2005-03-10 | Macrogenics, Inc. | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
WO2005056759A2 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
CN101987870B (en) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | Optimized Fc variants |
CA2577370A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
JP5255435B2 (en) | 2005-04-26 | 2013-08-07 | メディミューン,エルエルシー | Regulation of antibody effector function by hinge domain manipulation |
CN101213297B (en) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
KR101411165B1 (en) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
ES2526811T3 (en) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identification and modification of antibodies with Fc regions variants and methods of use of these |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
EP1945666B1 (en) | 2005-10-21 | 2013-03-27 | GTC Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
US8394926B2 (en) | 2005-12-21 | 2013-03-12 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA |
EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | Identification and engineering of antibodies with variant heavy chains and methods of using same |
IL177158A0 (en) | 2006-07-30 | 2008-01-20 | Assaf Klar | Method for designing and implementing improved longitudinal flexibility multilayered pipeline |
ES2457072T3 (en) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Optimized antibodies that select as target CD19 |
CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
WO2008121160A2 (en) | 2006-11-21 | 2008-10-09 | Xencor, Inc. | Optimized antibodies that target cd5 |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
WO2008091798A2 (en) | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
WO2008098115A2 (en) | 2007-02-07 | 2008-08-14 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
ES2659517T3 (en) | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Methods and compositions for inhibiting cells expressing CD32B |
KR101586617B1 (en) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | Antibodies to human programmed death receptor PD-1 |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
CN102076865B (en) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | The antibody reduced for the manufacture of core fucosylation and the method and composition of antibody derivatives |
CN102203125A (en) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1 antagonists and methods of use thereof |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
EP2703415B1 (en) | 2008-09-17 | 2019-03-06 | Xencor, Inc. | Compositions and methods for treating IgE-mediated disorders |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
WO2011035884A1 (en) | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
PT2606064E (en) | 2010-08-16 | 2015-06-08 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
EA029300B1 (en) | 2011-03-02 | 2018-03-30 | Роше Гликарт Аг | Antibody which binds membrane-bound human carcinoembryonic antigen, production and use thereof |
WO2013012414A1 (en) | 2011-07-18 | 2013-01-24 | Medimmune, Llc | Dosing regimens for treatment of cea-expressing cancers |
EA026924B1 (en) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
AU2012351751B2 (en) | 2011-10-19 | 2017-09-07 | Novimmune S.A. | Methods of purifying antibodies |
US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
BR122022015975B1 (en) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | MONOCLONAL ANTIBODIES, KIT FOR THE TREATMENT OF AN INDIVIDUAL AFFLICTED WITH A CANCER, PROCESS FOR MEASURING MEMBRANOUS PD-L1 ON ISOLATED TUMOR CELLS AND USE OF THE ANTIBODY OR A PORTION THAT BIDS TO THE ANTIGEN THEREOF |
CA2892585C (en) | 2012-12-03 | 2022-07-05 | Novimmune S.A. | Anti-cd47 antibodies and methods of use thereof |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
MY192312A (en) | 2013-02-26 | 2022-08-17 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
MX2015010843A (en) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules. |
CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
EP3096782A4 (en) | 2014-01-21 | 2017-07-26 | Medlmmune, LLC | Compositions and methods for modulating and redirecting immune responses |
US20160009805A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
DK3277821T3 (en) | 2015-03-31 | 2019-10-28 | Novimmune Sa | PROCEDURE FOR OPTIMIZING COLLECTION AND PRODUCTION OF HETERO-MULTIMATE PROTEIN COMPLEXS |
CR20180162A (en) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS |
GB2546072B (en) | 2016-01-05 | 2019-07-10 | Bja Trading Ltd | Attachment assembly and method of using same |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
US20200255515A1 (en) | 2016-05-09 | 2020-08-13 | Celgene Corporation | Cd47 antibodies and methods of use thereof |
CA3036564A1 (en) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
WO2018098384A1 (en) | 2016-11-22 | 2018-05-31 | Regents Of The University Of California | Segregation modulation for immunotherapy |
TWI816673B (en) | 2017-05-08 | 2023-10-01 | 大陸商上海津曼特生物科技有限公司 | Bispecific recombinant protein and application thereof |
CN111201238B (en) | 2017-07-21 | 2023-09-08 | 诺夫免疫股份有限公司 | Methods of producing multispecific antibody mixtures and methods of use thereof |
KR20210029158A (en) | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Bispecific antibodies to CEACAM5 and CD47 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
ES2967381T3 (en) | 2020-12-18 | 2024-04-30 | Lamkap Bio Beta Ag | Bispecific antibodies against CEACAM5 and CD47 |
-
2021
- 2021-12-17 ES ES21834934T patent/ES2967381T3/en active Active
- 2021-12-17 PL PL21834934.8T patent/PL4055055T3/en unknown
- 2021-12-17 HR HRP20240213TT patent/HRP20240213T1/en unknown
- 2021-12-17 CA CA3193210A patent/CA3193210A1/en active Pending
- 2021-12-17 IL IL301701A patent/IL301701A/en unknown
- 2021-12-17 WO PCT/IB2021/061983 patent/WO2022130348A1/en active Application Filing
- 2021-12-17 US US17/554,941 patent/US11753481B2/en active Active
- 2021-12-17 PE PE2023001907A patent/PE20231386A1/en unknown
- 2021-12-17 JP JP2023537025A patent/JP2024501809A/en active Pending
- 2021-12-17 RS RS20240190A patent/RS65211B1/en unknown
- 2021-12-17 AU AU2021400227A patent/AU2021400227A1/en active Pending
- 2021-12-17 EP EP21834934.8A patent/EP4055055B1/en active Active
- 2021-12-17 KR KR1020237021786A patent/KR20230121772A/en unknown
- 2021-12-17 MX MX2023007220A patent/MX2023007220A/en unknown
-
2023
- 2023-06-16 CL CL2023001797A patent/CL2023001797A1/en unknown
- 2023-07-07 CO CONC2023/0009100A patent/CO2023009100A2/en unknown
- 2023-07-31 US US18/362,511 patent/US20240101705A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2967381T3 (en) | 2024-04-30 |
US20220195067A1 (en) | 2022-06-23 |
EP4055055C0 (en) | 2023-11-22 |
IL301701A (en) | 2023-05-01 |
EP4055055B1 (en) | 2023-11-22 |
AU2021400227A1 (en) | 2023-04-27 |
EP4055055A1 (en) | 2022-09-14 |
RS65211B1 (en) | 2024-03-29 |
CA3193210A1 (en) | 2022-06-23 |
JP2024501809A (en) | 2024-01-16 |
MX2023007220A (en) | 2023-08-25 |
HRP20240213T1 (en) | 2024-04-26 |
PE20231386A1 (en) | 2023-09-12 |
AU2021400227A9 (en) | 2024-05-30 |
CO2023009100A2 (en) | 2023-08-18 |
WO2022130348A1 (en) | 2022-06-23 |
US20240101705A1 (en) | 2024-03-28 |
CL2023001797A1 (en) | 2024-02-09 |
US11753481B2 (en) | 2023-09-12 |
KR20230121772A (en) | 2023-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3802599C0 (en) | Bispecific antibodies against ceacam5 and cd47 | |
EP4055055C0 (en) | Bispecific antibodies against ceacam5 and cd47 | |
IL291482A (en) | Bispecific antibodies against ceacam5 and cd3 | |
RS64645B1 (en) | Antibodies against sars-cov-2 | |
IL290412B (en) | Novel cd47 monoclonal antibodies and uses thereof | |
EP3891187A4 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
EP4010378A4 (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
EP3753953A4 (en) | Cd47 single-domain antibody and use thereof | |
IL290255A (en) | Anti-ctla4/anti-pd-1 bispecific antibody and use thereof | |
ZA202105150B (en) | Conjugate comprising ligand and ceacam5 antibody fab fragment | |
EP3833693A4 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
EP4155320A4 (en) | Anti-b7h4 antibody, and bispecific antibody and use thereof | |
EP3919512A4 (en) | HUMANIZED ANTI-Abeta MONOCLONAL ANTIBODY AND APPLICATION THEREOF | |
EP4141033A4 (en) | Anti-cd73-anti-pd-1 bispecific antibody and use thereof | |
EP3688034A4 (en) | Bispecific antibodies against EGFR and PD-1 | |
EP4112722C0 (en) | Anti-vim carbapenemase hybridoma cell strain, monoclonal antibody, and application | |
EP4144370A4 (en) | Bispecific antibody | |
AU2017255888A1 (en) | Humanized anti-BASIGIN antibodies and the use thereof | |
EP3825334A4 (en) | Anti-her3 humanized monoclonal antibody | |
IL291049A (en) | Anti-cd47 monoclonal antibody and use thereof | |
IL289488A (en) | Monoclonal antibodies that bind egfrviii and their use | |
EP4004054A4 (en) | Anti-her2/anti-4-1bb bispecific antibody and use thereof | |
IL291082A (en) | Anti-vsig4 antibody or antigen binding fragment and uses thereof | |
EP3672635A4 (en) | Monoclonal antibodies against pathological alpha-synuclein, and methods using same | |
GB202203066D0 (en) | Anti-rage antibody |